6185.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 6月 2024 @ 17:08):
Our systems believe the stock currently is undervalued by 0.70% compare to its pairs and should correct upwards.

Stats
本日の出来高	360 785
平均出来高	1.30M
時価総額	6.82B
EPS	HKD-0.690 ( Q1 \| 2024-03-31 )
次の収益日	( HKD-0.400 ) 2024-08-27
Last Dividend	HKD0.937 ( 2022-07-13 )
Next Dividend	HKD0 ( N/A )
P/E	-2.97 (Sector) 0 (Industry) 0
ATR14	HKD0.0260 (0.13%)

0013.HK -0.72%

0239.HK 1.24%

0455.HK 1.96%

0512.HK -0.21%

0570.HK 0.83%

0719.HK 0.75%

0858.HK 2.56%

0867.HK 0.76%

0874.HK 0.24%

0911.HK -1.75%

1011.HK -10.26%

1312.HK 3.03%

1349.HK 0.56%

1498.HK 0.00%

1513.HK 0.78%

1558.HK 5.15%

1652.HK -2.02%

1681.HK 2.58%

2161.HK 5.00%

2196.HK 0.46%

2552.HK 2.70%

2633.HK 1.56%

2877.HK -1.79%

3737.HK 0.00%

6185.HK 0.72%

6896.HK -0.65%

8049.HK -0.76%

8329.HK 3.62%

8622.HK 0.00%

9989.HK 2.52%

相関 (AI algo v.1.1b): Undervalued: 0.70% HKD19.82 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.04 (neutral)

短: 0.00 (neutral)

Signal:(54.566) Neutral

Cansino Biologics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cansino Biologics Inc 相関 - 通貨/商品

-0.34
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.65
( moderate negative )

0.15
( neutral )

0.32
( neutral )

Cansino Biologics Inc 財務諸表

Annual	2023
収益:	HKD345.18M
総利益:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2023
収益:	HKD345.18M
総利益:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2022
収益:	HKD1.03B
総利益:	HKD-186.61M (-18.10 %)
EPS:	HKD-3.91

FY	2021
収益:	HKD4.30B
総利益:	HKD3.00B (69.85 %)
EPS:	HKD7.74

Financial Reports:

No articles found.

Cansino Biologics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.937 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Cansino Biologics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.937	2022-07-13
Last Dividend	HKD0.937	2022-07-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.937	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-29)

HKD0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
13 Jul 2022	HKD0.937	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1523.HK	Ex Dividend Knight	2023-08-09	Semi-Annually	0.00%
0057.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
6099.HK	Ex Dividend Junior	2023-07-14	Annually	0.00%
1052.HK	Ex Dividend Junior	2023-11-03	Annually	0.00%
2313.HK	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
0635.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
1788.HK	Ex Dividend Junior	2023-09-08	Semi-Annually	0.00%
0217.HK	Ex Dividend Junior	2023-07-05	Sporadic	0.00%
8635.HK	No Dividend Player	2023-08-02	Annually	0.00%
1277.HK	Ex Dividend Knight	2023-10-09	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.22	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.177	1.200	-5.89	-7.06	[0 - 0.3]
returnOnEquityTTM	-0.274	1.500	-4.16	-6.24	[0.1 - 1]
payoutRatioTTM	-0.0448	-1.000	-0.448	0.448	[0 - 1]
currentRatioTTM	2.39	0.800	3.05	2.44	[1 - 3]
quickRatioTTM	2.19	0.800	1.810	1.448	[0.8 - 2.5]
cashRatioTTM	1.228	1.500	4.29	6.43	[0.2 - 2]
debtRatioTTM	0.247	-1.500	5.88	-8.82	[0 - 0.6]
interestCoverageTTM	-22.80	1.000	-9.56	-9.56	[3 - 30]
operatingCashFlowPerShareTTM	-2.66	2.00	-0.885	-1.770	[0 - 30]
freeCashFlowPerShareTTM	-4.80	2.00	-2.40	-4.80	[0 - 20]
debtEquityRatioTTM	0.415	-1.500	8.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	-2.35	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-4.45	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.309	1.000	-2.83	-2.83	[0.2 - 2]
assetTurnoverTTM	0.0419	0.800	-3.05	-2.44	[0.5 - 2]
Total Score				-3.85

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.00	1.000	-0.404	0	[1 - 100]
returnOnEquityTTM	-0.274	2.50	-2.67	-6.24	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.80	2.00	-1.601	-4.80	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-2.66	2.00	-0.885	-1.770	[0 - 30]
payoutRatioTTM	-0.0448	1.500	-0.448	0.448	[0 - 1]
pegRatioTTM	-0.224	1.500	-4.83	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-1.824	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.00

Cansino Biologics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cansino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.